Tarceva

(erlotinib)

ApprovedSmall molecule

DDutch Society of Physicians for Pulmonology and Tuberculosis

Erlotinib is used to treat certain types of lung cancer and pancreatic cancer by blocking proteins that help cancer cells grow and survive.[2] Tarceva is currently approved and in use across 79 indications[4].[1]

Tarceva is one of 1336 small molecule programs targeting Glioma. It is currently in Approved.

Indications

621

Total Trials

Active Trials

1,335

Competitors

FDA Application

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[4][1]

Indication

GliomaActive, not recruiting

Polycythemia VeraActive, not recruiting

Small Cell CarcinomaActive, not recruiting

EpendymomaActive, not recruiting

Pancreatic NeoplasmActive, not recruiting

Clear Cell Renal CarcinomaApproved

Familial Adenomatous PolyposisActive, not recruiting

Ebola Hemorrhagic FeverApproved

ToxicityActive, not recruiting

Kidney CancerActive, not recruiting

GliomaPreclinical

Active, not recruiting

Polycythemia VeraPhase 2

Active, not recruiting

Small Cell CarcinomaPhase 2

Active, not recruiting

EpendymomaPhase 2

Active, not recruiting

Pancreatic NeoplasmApproved

Active, not recruiting

Clear Cell Renal CarcinomaApproved

Approved

Familial Adenomatous PolyposisPhase 2

Active, not recruiting

Ebola Hemorrhagic FeverApproved

Approved

ToxicityPhase 2

Active, not recruiting

Kidney CancerPhase 2

Active, not recruiting

Showing 10 of 79 indications

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Tarceva

DDutch Society of Physicians for Pulmonology and Tuberculosis

Approved

18 2

Tykerb

GSK

Preclinical

80 3

Avastin

Adenocard

1 5

Methylthioninium Chloride

PProvepharm SAS

Preclinical

3 6

MS Contin

HHikma Pharmaceuticals LLC

Preclinical

3 7

Zinecard

CChildren's Oncology Group

Preclinical

2 8

Nubain

AAultman Health Foundation

Preclinical

1 9

Apatinib Mesylate

BBukwang Pharmaceutical

Preclinical

3 10

QS21

MMemorial Sloan Kettering Cancer Center

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2026

Phase 1Active, not recruiting

Patients With Advanced Solid Tumors

NCT00045201

Q1 2027

Phase 2Recruiting

Trial

NCT03297606

Phase 1Active, not recruiting

Pancreatic Cancer

NCT00878163

Phase 1Active, not recruiting

Tumors

NCT05827614

Q4 2027

Phase 1Active, not recruiting

Advanced or Metastatic Solid Tumors

NCT04449874

Q2 2028

Phase 2Recruiting

Oral Cavity Cancer

NCT06997068

Clinical

Trials by Indication[1]

Non-Small Cell Lung Cancer50 trials

An Observational Study of Tarceva (Erlotinib) in Participants With Locally Advanced or Metastatic Adenocarcinoma Non-Small Cell Lung Cancer (ELEMENT)

Completed· Roche logo

Roche··NCT01836133·70 enrolled

A Randomized Phase 2 Study of Erlotinib + ARQ 197 Versus Erlotinib + Placebo in Previously Treated Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

Completed· Merck & Co. logo

Merck & Co.·Phase 2·NCT00777309·167 enrolled

A Study to Assess Biomarkers Impact on Participants Response to Erlotinib Treatment for First-line Non-Small Cell Lung Cancer With Endothelial Growth Factor Receptor (EGFR) Activating Mutations

Completed· Roche logo

Roche·Phase 2·NCT01153984·23 enrolled

Show 47 more trials

A Study to Assess the Survival of Non-small Cell Lung Cancer Patients Treated With Tarceva After Failed Chemotherapy Treatment

Terminated· Roche logo

Roche··NCT01990261·33 enrolled

A Study of Tarceva (Erlotinib) and Standard of Care Chemotherapy in Patients With Advanced, Recurrent, or Metastatic Non-Small Cell Lung Cancer (NSCLC)

Completed· Roche logo

Roche·Phase 3·NCT00556322·424 enrolled

MK2206 and Erlotinib Hydrochloride in Treating Patients With Advanced Non-Small Cell Lung Cancer Who Have Progressed After Previous Response to Erlotinib Hydrochloride Therapy

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT01294306·80 enrolled

Celecoxib and Erlotinib in Treating Former Smokers With Stage IIIB or Stage IV Non-Small Cell Lung Cancer

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT00088959·45 enrolled

AZD9291 Versus Gefitinib or Erlotinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer

Completed· AstraZeneca logo

AstraZeneca·Phase 3·NCT02296125·674 enrolled

Stereotactic Radiosurgery and Erlotinib in Treating Patients With Non-Small Cell Lung Cancer and Brain Metastases

Withdrawn·UUniversity of California, San Francisco·Phase 1·NCT00738335

Docetaxel and Erlotinib in Treating Patients With Advanced Non-Small Cell Lung Cancer or Other Solid Tumors

Completed·UUniversity of California, Davis·Phase 1/2·NCT00390429·81 enrolled

A Study of Tarceva for Use in Patients With Relapsed or Refractory Metastatic Non-Small Cell Lung Cancer

Terminated· Takeda logo

Takeda·Phase 2·NCT00283634

Hsp90 Inhibitor AUY922 and Erlotinib Hydrochloride in Treating Patients With Stage IIIB-IV Non-Small Cell Lung Cancer

Completed·NNorthwestern University·Phase 1/2·NCT01259089·38 enrolled

Erlotinib in Treating Patients With Advanced Non-Small Cell Lung Cancer

Completed·VVanderbilt-Ingram Cancer Center·Phase 2·NCT00416650·16 enrolled

Combination Chemotherapy, Bev, RT, and Erlotinib in Treating Patients With Stage III Non-Small Cell Lung Cancer

Completed·UUNC Lineberger Comprehensive Cancer Center·Phase 1/2·NCT00280150·46 enrolled

Erlotinib Hydrochloride With or Without Celecoxib in Treating Patients With Stage IIIB-IV Non-Small Cell Lung Cancer

Completed·—·Phase 2·NCT00499655·107 enrolled

RO4929097 and Erlotinib Hydrochloride in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer

Terminated·NNational Cancer Institute (NCI)·Phase 1·NCT01193881·16 enrolled

Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal Cancer

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT00397384·43 enrolled

S0636: Erlotinib and Bevacizumab in Never-Smokers With Stage IIIB or Stage IV Primary Non-Small Cell Lung Cancer

Completed·SSWOG Cancer Research Network·Phase 2·NCT00445848·89 enrolled

Phase I Dasatinib/Erlotinib in Recurrent Non-small Cell Lung Cancer (NSCLC)

Completed·HH. Lee Moffitt Cancer Center and Research Institute·Phase 1·NCT00444015·34 enrolled

Erlotinib and Radiation Therapy Plus Combination Chemotherapy in Treating Patients With Inoperable Stage III Non-Small Cell Lung Cancer

Terminated·NNational Cancer Institute (NCI)·Phase 1·NCT00042835·48 enrolled

Erlotinib in Treating Patients With Advanced Non-Small Cell Lung Cancer, Ovarian Cancer, or Squamous Cell Carcinoma of the Head and Neck

Completed·NNational Cancer Institute (NCI)·Phase 1/2·NCT00063895·80 enrolled

Pemetrexed Disodium and Carboplatin or Cisplatin With or Without Erlotinib Hydrochloride in Treating Patient With Stage IV Non-Small Cell Lung Cancer Resistant to First-Line Therapy With Erlotinib Hydrochloride or Gefitinib

Withdrawn·VVanderbilt-Ingram Cancer Center·Phase 2·NCT01928160

INC280 and Erlotinib Hydrochloride in Treating Patients With Non-small Cell Lung Cancer

Completed·UUniversity of California, Davis·Phase 1·NCT01911507·35 enrolled

Volociximab and Erlotinib in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer

Unknown status·JJonsson Comprehensive Cancer Center·Phase 2·NCT00278187

Study of Blood and Tissue Samples in Predicting Response to Second-Line Therapy Using Erlotinib Hydrochloride or Chemotherapy in Patients With Advanced Non-Small Cell Lung Cancer

Unknown status·IIstituto Scientifico H. San Raffaele·Phase 3·NCT00989690·275 enrolled

Pemetrexed or Docetaxel With or Without Erlotinib in Stage IIIB or Stage IV Non-Small Cell Lung Cancer

Completed·—·Phase 2·NCT00660816·46 enrolled

Carboplatin and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Followed by Radiation Therapy and Erlotinib in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed By Surgery

Completed·AAlliance for Clinical Trials in Oncology·Phase 2·NCT00553462·78 enrolled

Second Line Erlotinib (Tarceva) Plus Digoxin in Non-Small Cell Lung Cancer

Terminated·UUniversity of Louisville·Phase 2·NCT00281021·26 enrolled

Erlotinib Hydrochloride and Onalespib Lactate in Treating Patients With Recurrent or Metastatic EGFR-Mutant Non-small Cell Lung Cancer

Completed·NNational Cancer Institute (NCI)·Phase 1/2·NCT02535338·11 enrolled

Erlotinib Hydrochloride Before Surgery in Treating Patients With Stage III Non-Small Cell Lung Cancer

Terminated·—·Phase 2·NCT01857271·3 enrolled

A Study of Changes in FDG- and FLT-PET Imaging in Patients With Non-Small Cell Lung Cancer Following Treatment With Erlotinib

Completed· Roche logo

Roche·Phase 1/2·NCT00453362·88 enrolled

Erlotinib in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer

Completed·NNational Cancer Institute (NCI)·N/A·NCT00085280·129 enrolled

Erlotinib and Celecoxib in Treating Patients With Stage IIIB or Stage IV Recurrent Non-Small Cell Lung Cancer

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00062101·80 enrolled

Erlotinib in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer

Completed·UUniversity College, London·Phase 3·NCT00275132·670 enrolled

Radiation Therapy and Stereotactic Radiosurgery With or Without Temozolomide or Erlotinib in Treating Patients With Brain Metastases Secondary to Non-Small Cell Lung Cancer

Terminated·NNational Cancer Institute (NCI)·Phase 3·NCT00096265·126 enrolled

Prophylactic Cranial Irradiation in Erlotinib/Gefitinib-responders With Non-small Cell Lung Cancer (NSCLC) (RT1001)

Unknown status·ZZhejiang Cancer Hospital·Phase 3·NCT01158170·200 enrolled

Erlotinib Hydrochloride in Treating Non-Small Cell Lung Cancer That is Metastatic or Cannot be Removed by Surgery in Patients With HIV Infection

Terminated·NNational Cancer Institute (NCI)·Phase 1·NCT02134886·48 enrolled

Erlotinib, Paclitaxel, and Carboplatin in Treating Patients With Stage III, Stage IV, or Recurrent Non-Small Cell Lung Cancer

Completed·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 2·NCT00287989·86 enrolled

Erlotinib and SBRT in Treating Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Completed·UUniversity of Texas Southwestern Medical Center·Phase 2·NCT00547105·24 enrolled

Erlotinib and Momelotinib for the Treatment of Epidermal Growth Factor Receptor (EGFR) Mutated EGFR Tyrosine Kinase Inhibitor (TKI) Naive Metastatic Non-Small Cell Lung Cancer (NSCLC)

Terminated·—·Phase 1·NCT02206763·11 enrolled

A Study of First Line Treatment With Tarceva (Erlotinib) in Combination With Gemcitabine in Patients With Unresectable Advanced and/or Metastatic Non-Small Cell Lung Cancer

Completed· Roche logo

Roche·Phase 2·NCT00701558·20 enrolled

A Study of Bevacizumab in Combination With Standard of Care Treatment in Participants With Advanced Non-squamous Non-small Cell Lung Cancer (NSCLC)

Completed· Roche logo

Roche·Phase 3·NCT01351415·485 enrolled

Study of Erlotinib With or Without Investigational Drug (U3-1287) in Subjects With Advanced Non-small Cell Lung Cancer

Completed· Daiichi Sankyo logo

Daiichi Sankyo·Phase 1/2·NCT01211483·222 enrolled

Safety Study of Radiotherapy and Concurrent Erlotinib (Tarceva®) for Brain Metastases From a Non-Small Cell Lung Cancer

Completed·AAmsterdam UMC, location VUmc·Phase 1·NCT00536861·11 enrolled

Docetaxel, Cisplatin, and Erlotinib Hydrochloride in Treating Patients With Stage I-III Non-small Cell Lung Cancer Following Surgery

Completed·MM.D. Anderson Cancer Center·Phase 1·NCT00254384·50 enrolled

A Study of ASP8273 vs. Erlotinib or Gefitinib in First-line Treatment of Patients With Stage IIIB/IV Non-small Cell Lung Cancer Tumors With EGFR Activating Mutations

Terminated· Astellas logo

Astellas·Phase 3·NCT02588261·530 enrolled

An Expanded Access Program of Tarceva (Erlotinib) in Participants With Advanced Non-Small Cell Lung Cancer (NSCLC)

Completed· Roche logo

Roche·Phase 4·NCT00949910·6,586 enrolled

A Study of Tarceva (Erlotinib) in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer Following 4 Cycles of Platinum-based Chemotherapy Without Disease Progression

Completed· Roche logo

Roche·Phase 4·NCT01230710·51 enrolled

A Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy or Immunotherapy in Participants With Non-small Cell Lung Cancer (MK-3475-021/KEYNOTE-021)

Completed· Merck & Co. logo

Merck & Co.·Phase 1/2·NCT02039674·267 enrolled

A Study Evaluating Dalotuzumab (MK-0646) in Combination With Erlotinib for Participants With Non-Small Cell Lung Cancer (MK-0646-007)

Completed· Merck & Co. logo

Merck & Co.·Phase 2·NCT00654420·95 enrolled

Pancreatic Cancer21 trials

Study of Gemcitabine and Erlotinib Plus Sorafenib (GES) in Metastatic Pancreatic Cancer

Completed·NNYU Langone Health·Phase 2·NCT00696696·45 enrolled

Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed by the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed by Surgery

Completed·NNational Cancer Institute (NCI)·Phase 3·NCT01013649·546 enrolled

Gemcitabine With or Without Capecitabine and/or Radiation Therapy or Gemcitabine With or Without Erlotinib in Treating Patients With Locally Advanced Pancreatic Cancer That Cannot Be Removed by Surgery

Completed·GGERCOR - Multidisciplinary Oncology Cooperative Group·Phase 3·NCT00634725·820 enrolled

Show 18 more trials

Erlotinib, Gemcitabine, and Radiation Therapy in Treating Patients With Locally Advanced Unresectable Pancreatic Cancer

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT00063947·28 enrolled

GDC-0449 and Erlotinib Hydrochloride With or Without Gemcitabine Hydrochloride in Treating Patients With Metastatic Pancreatic Cancer or Solid Tumors That Cannot Be Removed by Surgery

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 1·NCT00878163·55 enrolled

Erlotinib in Treating Patients With Stage III or Stage IV Pancreatic Cancer

Terminated·RRoswell Park Cancer Institute·Phase 2·NCT00470535·18 enrolled

Erlotinib and Gemcitabine With or Without Panitumumab in Treating Patients With Metastatic Pancreatic Cancer

Completed·AAlliance for Clinical Trials in Oncology·Phase 2·NCT00550836·104 enrolled

Gemcitabine With/Out Erlotinib in Unresectable Locally Advanced/Metastatic Pancreatic Cancer

Completed·NNCIC Clinical Trials Group·Phase 3·NCT00026338·569 enrolled

Bevacizumab and Gemcitabine Combined With Either Cetuximab or Erlotinib in Treating Patients With Advanced Pancreatic Cancer

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00091026·143 enrolled

Erlotinib Hydrochloride in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery

Terminated·NNational Cancer Institute (NCI)·Phase 2·NCT00482625·6 enrolled

ChemoRT With Adjuvant Chemo in Pancreatic Cancer (TARCEVA)

Completed·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 2·NCT00313560·48 enrolled

A Dose-Escalation to Rash Study of Tarceva (Erlotinib) Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer

Completed· Roche logo

Roche·Phase 2·NCT00652366·467 enrolled

Gemcitabine, Capecitabine, and Erlotinib in Treating Patients With Advanced Pancreatic Cancer

Completed·CCentre Antoine Lacassagne·Phase 1·NCT00885066·30 enrolled

Bevacizumab and Erlotinib in Treating Patients With Metastatic Pancreatic Cancer That Did Not Respond to Previous Treatment With Gemcitabine

Completed·UUniversity of California, San Francisco·Phase 2·NCT00365144·36 enrolled

Genistein, Gemcitabine, and Erlotinib in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer

Completed·BBarbara Ann Karmanos Cancer Institute·Phase 2·NCT00376948·20 enrolled

Gemcitabine and Erlotinib Before and After Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery

Completed·AAlliance for Clinical Trials in Oncology·Phase 2·NCT00733746·123 enrolled

Gemcitabine Plus Erlotinib in RASH-positive Patients With Metastatic Pancreatic Cancer

Unknown status·LLudwig-Maximilians - University of Munich·Phase 2·NCT01729481·150 enrolled

Phase II Trial of Erlotinib in Advanced Pancreatic Cancer

Completed·UUniversity Health Network, Toronto·Phase 2·NCT00497224·51 enrolled

Metformin Combined With Chemotherapy for Pancreatic Cancer

Completed·—·Phase 2·NCT01210911·120 enrolled

A Biomarker Identification Trial of Tarceva (Erlotinib) in Patients With Advanced Pancreatic Cancer

Completed· Roche logo

Roche·Phase 2·NCT00674973·207 enrolled

Gemcitabine and Erlotinib in Treating Patients With Metastatic or Recurrent Pancreatic Cancer

Completed·UUniversity of California, Davis·Phase 2·NCT00810719·30 enrolled

Breast Cancer9 trials

Erlotinib Hydrochloride and Bevacizumab in Treating Patients With Stage IV Breast Cancer

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00054132·38 enrolled

Erlotinib and Gemcitabine in Treating Patients With Metastatic Breast Cancer Previously Treated With An Anthracycline and/or a Taxane

Completed·AAlliance for Clinical Trials in Oncology·Phase 2·NCT00059852·61 enrolled

Trastuzumab and Erlotinib as First-Line Therapy in Treating Women With Metastatic Breast Cancer Associated With HER2/Neu Overexpression

Completed·JJonsson Comprehensive Cancer Center·Phase 1/2·NCT00033514·27 enrolled

Show 6 more trials

A Study to Evaluate Erlotinib in Patients With Advanced or Metastatic Breast Cancer During or Following Chemotherapy

Completed· Roche logo

Roche·Phase 2·NCT00109265

Erlotinib Plus Chemotherapy for Treatment of Triple Negative Breast Cancer

Unknown status·UUniversity of Kansas Medical Center·Phase 2·NCT00491816·32 enrolled

Erlotinib in Treating Patients With Locally Advanced or Metastatic Breast Cancer

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00030537

Ph II Letrozole + OSI-774 (Tarceva) in Post-menopausal, w/ ER and/or PR-positive Met Breast Cancer.

Terminated·VVanderbilt-Ingram Cancer Center·Phase 2·NCT00611715·48 enrolled

Erlotinib in Treating Women Undergoing Surgery For Stage I, Stage II, or Stage III Breast Cancer

Terminated·BBarbara Ann Karmanos Cancer Institute·N/A·NCT00503841·44 enrolled

Erlotinib and Everolimus in Treating Patients With Metastatic Breast Cancer

Completed·VVanderbilt-Ingram Cancer Center·Phase 1·NCT00574366·14 enrolled

Lung Cancer9 trials

Lung-MAP: Rilotumumab and Erlotinib Hydrochloride or Erlotinib Hydrochloride Alone as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches

Terminated·SSWOG Cancer Research Network·Phase 2/3·NCT02926638·9 enrolled

Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer

Completed·SSWOG Cancer Research Network··NCT02154490·1,864 enrolled

Sorafenib/Erlotinib Versus Erlotinib Alone in Previously Treated Advanced Non-Small-Cell Lung Cancer (NSCLC)

Completed·SSCRI Development Innovations, LLC·Phase 2·NCT00600015·166 enrolled

Show 6 more trials

Study of Tarceva and Targretin Oral Capsules in Patients With Advanced Lung Cancer

Completed·KKonstantin Dragnev·Phase 2·NCT00125359·42 enrolled

LUX-Lung 8: A Phase III Trial of Afatinib (BIBW 2992) Versus Erlotinib for the Treatment of Squamous Cell Lung Cancer After at Least One Prior Platinum Based Chemotherapy

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 3·NCT01523587·795 enrolled

Erlotinib Is Being Studied With Or Without An Investigational Drug, PF-02341066, In Patients With Lung Cancer

Completed· Pfizer logo

Pfizer·Phase 1·NCT00965731·27 enrolled

Early Prediction of Therapeutic Response to Targeted Therapy in Stage IIIB/IV or Recurrent Lung Cancer Patients

Completed·UUniversity of Utah·Phase 1·NCT00708448·26 enrolled

Erlotinib Re-Challenge for Recurrent EGFR-mutant Lung Cancer in Patients Who Previously Received Adjuvant Erlotinib or Gefitinib

Terminated·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT01189435·2 enrolled

Study of Patritumab in Combination With Erlotinib in Subjects With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC). (HER3-Lung)

Terminated· Daiichi Sankyo logo

Daiichi Sankyo·Phase 3·NCT02134015·145 enrolled

Squamous Cell Carcinoma7 trials

Temsirolimus (Torisel®) and Erlotinib (Tarceva®) in Platinum-Refractory/Ineligible, Advanced, Squamous Cell Carcinoma

Terminated·NNew Mexico Cancer Research Alliance·Phase 2·NCT01009203·13 enrolled

Adjuvant Erlotinib After Completing Chemoradiotherapy in Locally Advanced Squamous Cell Carcinoma of the Head and Neck

Completed·NNCIC Clinical Trials Group·Phase 1·NCT00079053·19 enrolled

Combination Chemotherapy With or Without Erlotinib Hydrochloride in Treating Patients With Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT01064479·123 enrolled

Show 4 more trials

Erlotinib,Radiation and Cisplatin in Patients With Complete Resected Squamous Cell Carcinoma of the Head and Neck

Completed·GGrupo de Investigación Clínica en Oncología Radioterapia·Phase 3·NCT00442455·53 enrolled

Phase I Study of a Statin + Erlotinib for Advanced Solid Malignancies With Focus on Squamous Cell Carcinomas and NSCLC

Completed·OOttawa Hospital Research Institute·Phase 1·NCT00966472·24 enrolled

Erlotinib, Docetaxel, and Radiation Therapy in Stage III or Stage IV Squamous Cell Carcinoma of the Head and Neck

Completed·—·Phase 2·NCT00720304·43 enrolled

Erlotinib in Women With Squamous Cell Carcinoma of the Vulvar

Completed·—·Phase 2·NCT00476476·41 enrolled

70 more indications

Glioblastoma Multiforme5 trials

A Study of the Safety and Efficacy of Tarceva in Patients With First Relapse of Grade IV Glioma (Glioblastoma Multiforme)

Completed· Roche logo

Roche·Phase 2·NCT00337883·110 enrolled

Erlotinib and Sorafenib in Treating Patients With Progressive or Recurrent Glioblastoma Multiforme

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00445588·56 enrolled

Erlotinib in Treating Patients With Recurrent or Progressive Glioblastoma Multiforme

Unknown status·TThe Cleveland Clinic·Phase 2·NCT00054496·73 enrolled

Show 2 more trials

Erlotinib in Treating Patients With Progressive Glioblastoma Multiforme

Terminated·UUNC Lineberger Comprehensive Cancer Center·Phase 1·NCT00227032·10 enrolled

Erlotinib Compared With Temozolomide or Carmustine in Treating Patients With Recurrent Glioblastoma Multiforme

Completed·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 2·NCT00086879·110 enrolled

Patients With Advanced Solid Tumors4 trials

Erlotinib in Combination With Select Tyrosine Kinase Inhibitors in Adult Patients With Advanced Solid Tumors

Withdrawn·NNational Cancer Institute (NCI)·Phase 1·NCT06161558

A Study of the Safety and Pharmacology of GDC-0941 in Combination With Erlotinib in Patients With Advanced Solid Tumors

Completed· Roche logo

Roche·Phase 1·NCT00975182·58 enrolled

Erlotinib Hydrochloride and Irinotecan Hydrochloride in Treating Patients With Advanced Solid Tumors

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 1·NCT00045201·60 enrolled

Show 1 more trial

Erlotinib, Trastuzumab, and Paclitaxel in Treating Patients With Advanced Solid Tumors

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT00042809·40 enrolled

Head and Neck Cancer3 trials

Erlotinib (Tarceva) During First Line Standard Platinum Containing Chemo for Advanced Squamous Cell Head and Neck Cancer

Terminated·HHenry Ford Health System·Phase 2/3·NCT00448240·6 enrolled

Erlotinib and Surgery in Treating Patients With Head and Neck Cancer That Can Be Removed by Surgery

Completed·WWake Forest University Health Sciences·Phase 1·NCT00601913·24 enrolled

Cisplatin and Radiation Therapy With or Without Erlotinib Hydrochloride in Treating Patients With Stage III or Stage IV Head and Neck Cancer

Completed·UUniversity of Washington·Phase 2·NCT00410826·204 enrolled

Small Cell Lung Cancer3 trials

Trial of Pemetrexed Versus Erlotinib in Pretreated Patients With Non Small Cell Lung Cancer (NSCLC)

Completed·HHellenic Oncology Research Group·Phase 3·NCT00440414·320 enrolled

2nd Line Erlotinib Treatment With (Out) Chemotherapy of Advanced Non Small Cell Lung Cancer (NSCLC)

Completed·DDutch Society of Physicians for Pulmonology and Tuberculosis·Phase 2·NCT00835471·195 enrolled

Erlotinib and Sequential Positron Emission Tomography (PET) in Advanced Non Small Cell Lung Cancer (NSCLC)

Unknown status·LLung Cancer Group Cologne·Phase 2·NCT00568841·40 enrolled

Malignant Glioma3 trials

Ph II Erlotinib + Sirolimus for Pts w Recurrent Malignant Glioma Multiforme

Completed·—·Phase 2·NCT00672243·32 enrolled

Erlotinib and Sirolimus in Treating Patients With Recurrent Malignant Glioma

Completed·JJonsson Comprehensive Cancer Center·Phase 1·NCT00509431·19 enrolled

Erlotinib Hydrochloride and Isotretinoin in Treating Patients With Recurrent Malignant Glioma

Terminated·WWake Forest University Health Sciences·Phase 1·NCT01103375·5 enrolled

Brain Metastases3 trials

QOL-Stereotactic RadioSurgery, Temozolomide + Erlotinib-Rx of 1-3 Brain Metastases in NSCLC

Withdrawn·UUniversity of Medicine and Dentistry of New Jersey·Phase 2·NCT00385398

WBRT & Erlotinib in Advanced NSCLC and Brain Metastases

Terminated·UUniversity College, London·Phase 2·NCT00554775·80 enrolled

Erlotinib With Concurrent Brain Radiotherapy and Secondary Brain Radiotherapy After Recurrence With Erlotinib in NSCLC Non-increased-intracranial-pressure Symptomatic Brain Metastases

Unknown status·WWu Jieping Medical Foundation·Phase 2·NCT01763385·210 enrolled

Advanced NSCLC3 trials

Study of IRX4204 With Erlotinib in Previously Treated Advanced NSCLC

Terminated·IIo Therapeutics·Phase 1·NCT02991651·12 enrolled

A Study of Tarceva vs. Avastin+Tarceva for Advanced NSCLC With EGFR m(+)

Unknown status·NNational Cancer Center, Korea·Phase 2·NCT03126799·128 enrolled

BATTLE Program: Erlotinib in Previously Treated Subjects With Advanced NSCLC

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT00410059·59 enrolled

Advanced Solid Tumors2 trials

A Safety Study in Participants With Advanced Solid Tumors

Terminated· Eli Lilly logo

Eli Lilly·Phase 1·NCT01284335·234 enrolled

Phase I Study of Indibulin in Combination With Erlotinib in Advanced Solid Tumors

Unknown status·AAlaunos Therapeutics·Phase 1·NCT00591383·10 enrolled

Trial2 trials

Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR)

Recruiting·CCanadian Cancer Trials Group·Phase 2·NCT03297606·720 enrolled

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

Terminated·OOHSU Knight Cancer Institute·Phase 1·NCT03878524·2 enrolled

Growth2 trials

A Study of Tarceva (Erlotinib) in Patients With Locally Advanced, Metastatic or Recurrent Non-Small Cell Cancer Who Present Epidermal Growth Factor Receptor Mutations

Completed· Roche logo

Roche·Phase 2·NCT01372384·6 enrolled

An Umbrella, Modular Study Based on Epidermal Growth Factor Receptor (EGFR) Mutation Status

Completed·MM.D. Anderson Cancer Center·Phase 1·NCT00903734·16 enrolled

Gastroesophageal Junction2 trials

Erlotinib and Avastin in Patients With Cancer of the Esophagus or Gastroesophageal Junction

Terminated·WWashington University School of Medicine·Phase 2·NCT00442507·6 enrolled

Oxaliplatin, Fluorouracil, Erlotinib Hydrochloride, and Radiation Therapy Before Surgery and Erlotinib Hydrochloride After Surgery in Treating Patients With Locally Advanced Cancer of the Esophagus or Gastroesophageal Junction

Completed·WWake Forest University Health Sciences·Phase 1·NCT01561014·9 enrolled

Liver Cancer2 trials

Erlotinib in Treating Patients With Liver Cancer That Cannot be Surgically Removed

Terminated·NNational Cancer Institute (NCI)·Phase 2·NCT00047333·80 enrolled

Bevacizumab and Erlotinib or Sorafenib as First-Line Therapy in Treating Patients With Advanced Liver Cancer

Completed·MMedical University of South Carolina·Phase 2·NCT00881751·95 enrolled

Recurrent Head and Neck Cancer2 trials

Erlotinib Plus Docetaxel in Treating Patients With Locally Advanced, Metastatic, or Recurrent Head and Neck Cancer

Completed·NNational Cancer Institute (NCI)·Phase 1/2·NCT00055770·45 enrolled

Erlotinib, Celecoxib and Reirradiation for Recurrent Head and Neck Cancer

Completed·JJohnny Kao·Phase 1/2·NCT00970502·15 enrolled

Metastatic Colorectal Cancer2 trials

Erlotinib and Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer

Completed·MMemorial Sloan Kettering Cancer Center·Phase 1/2·NCT00049101

Erlotinib in Treating Patients With Recurrent or Metastatic Colorectal Cancer

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00032110·30 enrolled

Colorectal Cancer2 trials

Dual Epidermal Growth Factor Receptor Inhibition With Erlotinib and Panitumumab With or Without Chemotherapy for Advanced Colorectal Cancer

Completed·NNorthwestern University·Phase 2·NCT00940316·28 enrolled

A Phase I, Pharmacological, and Biological Study of OSI-774 in Combination With FOLFOX 4 (5-FU, Leucovorin, and Oxaliplatin) and Bevacizumab (Avastin) in Patients With Advanced Colorectal Cancer

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT00060411·24 enrolled

Bevacizumab2 trials

Molecular Imaging With Erlotinib and Bevacizumab

Completed·UUniversity of Cologne·Phase 2·NCT01047059·40 enrolled

S0635: Erlotinib and Bevacizumab in Stage IIIB and IV Bronchioloalveolar Carcinoma

Completed·SSWOG Cancer Research Network·Phase 2·NCT00436332·84 enrolled

NSCLC2 trials

Erlotinib and Sunitinib in NSCLC

Completed·UUniversity of Wisconsin, Madison·Phase 1·NCT00581789·11 enrolled

A Comparison Between BMS-690514 and Erlotinib in Patients Who Were Previously Treated for NSCLC

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 2·NCT00743938·141 enrolled

Kidney Cancer2 trials

Tivantinib With or Without Erlotinib Hydrochloride in Treating Patients With Metastatic or Locally Advanced Kidney Cancer That Cannot Be Removed by Surgery

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT01688973·55 enrolled

Sunitinib and Erlotinib in Treating Patients With Unresectable or Metastatic Kidney Cancer

Completed·OOHSU Knight Cancer Institute·Phase 2·NCT00425386·60 enrolled

Intestinal Cancer2 trials

Avastin and Tarceva for Upper Gastrointestinal Cancers

Completed·RRigshospitalet, Denmark·Phase 2·NCT00350753·126 enrolled

A Pilot Study of Genomic Sequencing Guided Individualized Therapy in Gastrointestinal Cancers, GITIC Study

Unknown status·SSun Yat-sen University·N/A·NCT02013089·50 enrolled

Lung Adenocarcinoma2 trials

Cetuximab in Patients With Lung Adenocarcinoma Receiving Erlotinib That Have Developed "Acquired Resistance" to Erlotinib

Completed·MMemorial Sloan Kettering Cancer Center·Phase 1/2·NCT00716456·21 enrolled

A Phase II Study to Assess Efficacy of Combined Treatment With Erlotinib (Tarceva) and Silybin-phytosome (Siliphos) in Patients With EGFR Mutant Lung Adenocarcinoma

Unknown status·MMedicalLogic·Phase 2·NCT02146118·42 enrolled

Adenocarcinoma2 trials

A Phase II Study of TX Regimen as First-line Treatment for Asian Elderly Patients With Advanced Adenocarcinoma of Lung

Completed·SSun Yat-sen University·Phase 2·NCT00816868·62 enrolled

Individualized Treatment Based on Epidermal Growth Factor Receptor Mutations and Level of BRCA1 Expression in Advanced Adenocarcinoma

Completed·SSpanish Lung Cancer Group·N/A·NCT00883480·153 enrolled

Head and Neck Squamous Cell Carcinoma2 trials

Study of Chemotherapy With Cisplatin/Carboplatin, and Docetaxel With or Without Erlotinib in Patients With Head and Neck Squamous Cell Carcinomas Amenable for Surgical Resection

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT01927744·55 enrolled

Erlotinib and Docetaxel With Concomitant Boost Radiation Therapy (XRT) for Head and Neck Squamous Cell Carcinoma (HNSCC)

Completed·MM.D. Anderson Cancer Center·Phase 1·NCT00113347·10 enrolled

Biliary Tract Cancer1 trial

Pemetrexed in Combination With Erlotinib as a Salvage Treatment in Patients With Metastatic Biliary Tract Cancer (BTC) Who Failed Gemcitabine Containing Chemotherapy: A Phase II Single Arm Prospective Study

Unknown status·SSamsung Medical Center·Phase 2·NCT03110484·44 enrolled

Toxicity1 trial

A Study of Tarceva (Erlotinib) in Combination With Gemcitabine in Unresectable and/or Metastatic Cancer of the Pancreas: Relationship Between Skin Toxicity and Survival

Completed· Roche logo

Roche·Phase 2·NCT00461708·153 enrolled

Mesothelioma1 trial

Bevacizumab (Avastin) and Erlotinib (Tarceva) in Previously Treated Mesothelioma

Completed·—·Phase 2·NCT00137826·37 enrolled

Refractory Solid Tumors1 trial

PK Trial of Sorafenib & Erlotinib in Patients With Refractory Solid Tumors

Completed·SSCRI Development Innovations, LLC·Phase 1·NCT00759928·48 enrolled

Sclerosing Cholangitis1 trial

Erlotinib for Chemoprevention in Trisomy 7 Positive Primary Sclerosing Cholangitis (PSC)

Completed·MMayo Clinic·Phase 1·NCT00955149·6 enrolled

Immunotherapy1 trial

The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy

Unknown status·FFondazione per la Medicina Personalizzata·Phase 2·NCT04591431·400 enrolled

Locally-advanced Rectal Cancer1 trial

Bevacizumab, Erlotinib, and Capecitabine for Locally Advanced Rectal Cancer

Completed·MM.D. Anderson Cancer Center·Phase 1·NCT00543842·19 enrolled

Recurrent or Refractory Solid Tumors1 trial

Erlotinib and Temozolomide in Treating Young Patients With Recurrent or Refractory Solid Tumors

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT00077454·95 enrolled

Urothelial Cancer1 trial

Erlotinib Hydrochloride in Treating Participants With Muscle Invasive or Recurrent Urothelial Cancer

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT00749892·34 enrolled

Cholangiocarcinoma1 trial

Sorafenib Tosylate and Erlotinib Hydrochloride in Treating Patients With Locally Advanced, Unresectable, or Metastatic Gallbladder Cancer or Cholangiocarcinoma

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT01093222·40 enrolled

Completed·UUNC Lineberger Comprehensive Cancer Center·Phase 1·NCT00320073·41 enrolled

Gastroesophageal Junction Cancer1 trial

Erlotinib in Treating Patients With Locally Advanced or Metastatic Stomach Cancer or Gastroesophageal Junction Cancer

Completed·SSWOG Cancer Research Network·Phase 2·NCT00032123

Unresectable1 trial

Bevacizumab and Erlotinib Hydrochloride in Treating Patients With Metastatic or Unresectable Biliary Tumors

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00356889·56 enrolled

Solid Tumor Malignancies1 trial

A Phase 1 Protocol of 5-Azacytidine and Erlotinib in Advanced Solid Tumor Malignancies

Completed·NNew Mexico Cancer Research Alliance·Phase 1·NCT00996515·30 enrolled

Radiotherapy1 trial

Targeted Treatment With Intercalated Radiotherapy in EGFR-mutant IIIA/IIIB NSCLC

Unknown status·GGuangdong Provincial People's Hospital·Phase 2/3·NCT03074864·90 enrolled

Glioma1 trial

Erlotinib Alone or in Combination With Radiation Therapy in Treating Young Patients With Refractory or Relapsed Malignant Brain Tumors or Newly Diagnosed Brain Stem Glioma

Unknown status·CChildren's Cancer and Leukaemia Group·Phase 1·NCT00360854·48 enrolled

Elderly Patients1 trial

Ph II Gemcitabine, Erlotinib, and Gemcitabine With Erlotinib/Elderly Patients W/ IIIB/IV NSCLC

Completed·UUNC Lineberger Comprehensive Cancer Center·Phase 2·NCT00283244·147 enrolled

Esophageal Cancer1 trial

Erlotinib Hydrochloride in Treating Patients With Advanced Esophageal Cancer or Stomach Cancer

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00045526·48 enrolled

Recurrent Cancer1 trial

Erlotinib in Treating Patients With Persistent or Recurrent Cancer of the Cervix

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00031993·51 enrolled

Melanoma1 trial

Erlotinib and Bevacizumab in Treating Patients With Stage IV Melanoma

Completed·VVanderbilt-Ingram Cancer Center·Phase 2·NCT00466687·34 enrolled

Cutaneous Squamous Cell Carcinoma1 trial

Phase I/II Study of Postoperative Adjuvant Chemoradiation for Advanced-Stage Cutaneous Squamous Cell Carcinoma of the Head and Neck (cSCCHN)

Withdrawn·OOHSU Knight Cancer Institute·Phase 1/2·NCT01465815

Oral Cavity Cancer1 trial

Methotrexate, Erlotinib, and Celecoxib for the Treatment of Recurrent/Metastatic Oral Cavity Cancer in a Rural Midwest United States Population

Recruiting·MMayo Clinic·Phase 2·NCT06997068·25 enrolled

Renal Cell Carcinoma1 trial

Erlotinib and Sirolimus for the Treatment of Metastatic Renal Cell Carcinoma

Completed·UUniversity of Colorado, Denver·Phase 2·NCT00353301·25 enrolled

Unresectable Solid Tumor1 trial

Sorafenib and Erlotinib in Treating Patients With Metastatic or Unresectable Solid Tumors

Completed·UUniversity Health Network, Toronto·Phase 1·NCT00126620·17 enrolled

Renal Cell Cancer1 trial

Erlotinib in Treating Patients With Locally Advanced or Metastatic Papillary Renal Cell Cancer

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00060307·40 enrolled

Head and Neck Squamous Cell Cancer1 trial

Carboplatin, Paclitaxel, Cetuximab, and Erlotinib Hydrochloride in Treating Patients With Metastatic or Recurrent Head and Neck Squamous Cell Cancer

Completed·FFox Chase Cancer Center·Phase 2·NCT01316757·24 enrolled

Squamous Cell Cancer of the Head and Neck1 trial

Erlotinib Hydrochloride and Radiation Therapy in Stage III-IV Squamous Cell Cancer of the Head and Neck

Terminated·—·Phase 2·NCT01192815·2 enrolled

Cancer1 trial

Erlotinib Hydrochloride in Preventing Cancer in Patients With Precancerous Lesions of the Lung

Terminated·NNational Cancer Institute (NCI)·Phase 1·NCT01013831·60 enrolled

Barrett Esophagus1 trial

Erlotinib in Treating Patients With Barrett Esophagus

Unknown status·—·Phase 1·NCT00566800·25 enrolled

Clinical Trial1 trial

ProTarget - A Danish Nationwide Clinical Trial on Targeted Cancer Treatment Based on Genomic Profiling

Recruiting·UUlrik Lassen·Phase 2·NCT04341181·300 enrolled

Advanced or Metastatic Solid Tumors1 trial

A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-6036 Alone or in Combination in Participants With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation

Active, not recruiting· Roche logo

Roche·Phase 1·NCT04449874·498 enrolled

Diffuse Intrinsic Pontine Glioma1 trial

Molecularly Determined Treatment of Diffuse Intrinsic Pontine Gliomas (DIPG)

Terminated·—·Phase 2·NCT01182350·53 enrolled

NSCLC Stage III1 trial

Erlotinib as 1st Line Treatment in NSCLC Stage IIIB/IV

Completed·HHellenic Oncology Research Group·Phase 2·NCT00615758·50 enrolled

Phase 11 trial

Phase 1 Trial With SIR-Spheres and Cetuximab +/- Erlotinib

Withdrawn·MM.D. Anderson Cancer Center·Phase 1·NCT01432119

Carcinoma1 trial

Therapeutic Strategy in Advanced Bronchioloalveolar Carcinoma

Completed·IIntergroupe Francophone de Cancerologie Thoracique·Phase 2·NCT00384826·133 enrolled

Solid Tumors1 trial

Safety Study of XL765 (SAR245409) in Combination With Erlotinib in Adults With Solid Tumors

Completed· Sanofi logo

Sanofi·Phase 1·NCT00777699·80 enrolled

Pediatric Patients1 trial

Selecting Patient-Specific Biologically Targeted Therapy for Pediatric Patients With Refractory Or Recurrent Brain Tumors

Unknown status·SSeattle Children's Hospital·N/A·NCT02015728·20 enrolled

First Line Therapy1 trial

EGFR-TKIs Combine Chemotherapy as First-line Therapy for Patients With Advanced EGFR Mutation-positive NSCLC

Unknown status·FFujian Cancer Hospital·Phase 3·NCT02886195·120 enrolled

Oral1 trial

Single-agent Erlotinib in Patients Previously Treated With Oral Etoposide in Protocol OSI-774-205

Terminated·OOSI Pharmaceuticals·Phase 2·NCT01247922·4 enrolled

EGFR Mutation1 trial

A Phase I/IB Trial of MEK162 in Combination With Erlotinib in NSCLC Harboring KRAS or EGFR Mutation

Completed·HH. Lee Moffitt Cancer Center and Research Institute·Phase 1·NCT01859026·43 enrolled

Advanced Cancer1 trial

A Study of LY2875358 in Japanese Participants With Advanced Cancer

Completed· Eli Lilly logo

Eli Lilly·Phase 1·NCT01602289·17 enrolled

Carcinoma of Unknown Primary1 trial

Paclitaxel/Carboplatin Plus Bevacizumab/Erlotinib in the First Line Treatment of Carcinoma of Unknown Primary Site

Completed·SSCRI Development Innovations, LLC·Phase 2·NCT00360360·60 enrolled

Gemcitabine1 trial

Gemcitabine, Oxaliplatin, Tarceva &/or Cisplatin in HCC & Biliary Tree Cancers

Terminated·NNew Mexico Cancer Research Alliance·Phase 2·NCT00832637·33 enrolled

Tumors1 trial

Study of the CHK1 Inhibitor BBI-355, an ecDNA-directed Therapy (ecDTx), and the RNR Inhibitor BBI-825, in Subjects With Tumors With Oncogene Amplifications

Active, not recruiting·BBoundless Bio, Inc.·Phase 1·NCT05827614·85 enrolled

Efficacy and Safety1 trial

Efficacy and Safety of Precision Therapy in Refractory Tumor

Unknown status·BBaodong Qin·Phase 2·NCT03239015·300 enrolled

Unspecified3 trials

The Continuation of Erlotinib

Unknown status·SSamsung Medical Center·Phase 2·NCT01130779·23 enrolled

Study of Erlotinib in Combination With Dasatinib

Completed·MM.D. Anderson Cancer Center·Phase 1·NCT00895128·65 enrolled

GSK1120212 Rollover Study

Terminated· Novartis logo

Novartis·Phase 2·NCT01376310·159 enrolled

Regulatory

FDA Approval Timeline[5]

Nov 18, 2004

TARCEVA

NDA NDA021743

Sources

References

[1]
ClinicalTrials.gov — 621 trial records for erlotinib. U.S. National Library of Medicine, National Institutes of Health.
[2]
MedlinePlus Drug Information — Tarceva drug information. U.S. National Library of Medicine, National Institutes of Health.
[3]
ChEMBL — erlotinib compound record. European Bioinformatics Institute (EMBL-EBI).
[4]
Open Targets Platform — Drug–disease associations for erlotinib. EMBL-EBI & Wellcome Sanger Institute.
[5]
OpenFDA — FDA approval records (NDA NDA021743). U.S. Food & Drug Administration.
[6]
SEC EDGAR — Dutch Society of Physicians for Pulmonology and Tuberculosis company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Mechanism of Action: Epidermal Growth Factor Receptor Erbb1 Inhibitor[3]
Modality: Small molecule[3]
Highest Phase: Approved[1]
Company: DDutch Society of Physicians for Pulmonology and Tuberculosis

Tarceva

Status by Indication[4][1]

Competitive Landscape

Expected Milestones

Q3 2026

Q1 2027

Q4 2027

Q2 2028

Trials by Indication[1]

Non-Small Cell Lung Cancer50 trials

Pancreatic Cancer21 trials

Breast Cancer9 trials

Lung Cancer9 trials

Squamous Cell Carcinoma7 trials

Glioblastoma Multiforme5 trials

Patients With Advanced Solid Tumors4 trials

Head and Neck Cancer3 trials

Small Cell Lung Cancer3 trials

Malignant Glioma3 trials

Brain Metastases3 trials

Advanced NSCLC3 trials

Advanced Solid Tumors2 trials

Trial2 trials

Growth2 trials

Gastroesophageal Junction2 trials

Liver Cancer2 trials

Recurrent Head and Neck Cancer2 trials

Metastatic Colorectal Cancer2 trials

Colorectal Cancer2 trials

Bevacizumab2 trials

NSCLC2 trials

Kidney Cancer2 trials

Intestinal Cancer2 trials

Lung Adenocarcinoma2 trials

Adenocarcinoma2 trials

Head and Neck Squamous Cell Carcinoma2 trials

Biliary Tract Cancer1 trial

Toxicity1 trial

Mesothelioma1 trial

Refractory Solid Tumors1 trial

Sclerosing Cholangitis1 trial

Immunotherapy1 trial

Locally-advanced Rectal Cancer1 trial

Recurrent or Refractory Solid Tumors1 trial

Urothelial Cancer1 trial

Cholangiocarcinoma1 trial

Fallopian Tube Cancer1 trial

Cervical Cancer1 trial

Metastatic Solid Tumors1 trial

Gastroesophageal Junction Cancer1 trial

Unresectable1 trial

Solid Tumor Malignancies1 trial

Radiotherapy1 trial

Glioma1 trial

Elderly Patients1 trial

Esophageal Cancer1 trial

Recurrent Cancer1 trial

Melanoma1 trial

Cutaneous Squamous Cell Carcinoma1 trial

Oral Cavity Cancer1 trial

Renal Cell Carcinoma1 trial

Unresectable Solid Tumor1 trial

Renal Cell Cancer1 trial

Head and Neck Squamous Cell Cancer1 trial

Squamous Cell Cancer of the Head and Neck1 trial

Cancer1 trial

Barrett Esophagus1 trial

Clinical Trial1 trial

Advanced or Metastatic Solid Tumors1 trial

Diffuse Intrinsic Pontine Glioma1 trial

NSCLC Stage III1 trial

Phase 11 trial

Carcinoma1 trial

Solid Tumors1 trial

Pediatric Patients1 trial

First Line Therapy1 trial

Oral1 trial

EGFR Mutation1 trial

Advanced Cancer1 trial

Carcinoma of Unknown Primary1 trial